Ulm

Futó vizsgálatok

• Toboroz

  An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  NCT07720284· 3. fázis· Forrás

• Toboroz

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  NCT06542250· 1/2. fázis· Forrás

• Toboroz

  NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

  NCT06494540· Forrás

• Fut, nem toboroz

  Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany

  NCT06336330· Forrás

• Toboroz

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· 3. fázis· Forrás

• Fut, nem toboroz

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· 3. fázis· Forrás

• Toboroz

  PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

  NCT05573893· Forrás

• Fut, nem toboroz

  Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer

  NCT04830709· Forrás

• Fut, nem toboroz

  Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

  NCT03732820· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

  NCT02970318· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

  NCT02477696· 3. fázis· Forrás

• Fut, nem toboroz

  Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

  NCT02453282· 3. fázis· Forrás

• Fut, nem toboroz

  Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• 2-es típusú cukorbetegség1 toboroz
• Áttétes emlőrák1 toboroz
• Elhízás1 toboroz
• Fej-nyaki daganatok1 toboroz
• Follikuláris limfóma1 toboroz
• Hólyagrák1 toboroz
• Köpenysejtes limfóma1 toboroz
• Krónikus limfoid leukémia (CLL)1 toboroz
• Tüdőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  REported Outcomes in COPD With Trixeo in Real worlD in Germany

  NCT05311306· Forrás

• Lezárult

  Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

  NCT04469465· 3. fázis· Forrás

• Lezárult

  Long-Term Evaluation of BIIB067 (Tofersen)

  NCT03070119· 3. fázis· Forrás